Ibrutinib
- Catalog NO.:A852882
- CAS No. : 936563-96-1
- Molecular Formula:C25H24N6O2
- Molecular Weight: 440.5
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 936563-96-1 | Appearance | |
Catalog Number | A852882 | MDL Number | MFCD20261150 |
Molecular Formula | C25H24N6O2 | Molecular Weight | 440.5 |
Boiling Point | 715.0±60.0°C at 760 mmHg | Melting Point | |
Flash Point | Density | 1.3 | |
Synonyms | PCI 32765;1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one;Ibrutinib (PCI-32765) | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H315; H319; H335 | Class | |
Precautionary Statements | P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501 | Packing Group |
Description
Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma. |